血管紧张素II 1型受体阻断与大鼠皮肤瘢痕形成减少相关
该研究在大鼠模型中检验氯沙坦能否减少术后皮肤瘢痕。体外实验显示氯沙坦降低人真皮成纤维细胞收缩、迁移及促纤维化基因表达,并减少单核细胞迁移黏附。体内实验显示氯沙坦组瘢痕横截面积、隆起指数及α-SMA、CD68免疫染色均低于对照组。
要点
- 氯沙坦可降低人真皮成纤维细胞收缩活性、迁移及促纤维化基因表达。
- 氯沙坦减少单核细胞向氯沙坦处理成纤维细胞的迁移与黏附。
- 大鼠体内氯沙坦组瘢痕横截面积、隆起指数及α-SMA、CD68免疫染色降低。
核心结论
- 氯沙坦降低肌成纤维细胞活性并减少单核细胞向皮肤瘢痕的迁移。
- 研究结果支持氯沙坦作为预防增生性瘢痕的潜在新疗法。
研究设计与样本
- 体外实验:人真皮成纤维细胞经氯沙坦处理,用calcein、胶原凝胶、划痕和qRT-PCR检测活力、收缩、迁移及促纤维化基因转录。
- 体外实验:检测单核细胞对氯沙坦处理及对照成纤维细胞的迁移与黏附。
- 体内实验:采用机械牵张增生性瘢痕模型,大鼠背部切口闭合后3天随机饮水中给予或不给予氯沙坦(1 mg/kg per day;每组n=6)。
- 体内实验:牵张装置应用并激活至第14天,第28天分析瘢痕横截面积、隆起指数及α-SMA和CD68免疫染色。
主要发现
- 氯沙坦处理的人真皮成纤维细胞较对照显示收缩活性、迁移及TGF-β1、I型胶原和MCP-1基因表达降低(p < 0.05)。
- 单核细胞对氯沙坦处理成纤维细胞的迁移和黏附减少(p < 0.01)。
- 与对照相比,氯沙坦处理大鼠瘢痕横截面积减小(19.4 ± 3.1 mm versus 45.0 ± 5.2 mm;p = 0.002)。
- 与对照相比,氯沙坦处理大鼠瘢痕隆起指数降低(1.5 ± 0.1 versus 2.6 ± 0.3;p = 0.003)。
- 与对照相比,氯沙坦处理大鼠瘢痕α-SMA和CD68免疫染色降低(p < 0.001)。
临床怎么用
- 氯沙坦可能作为预防增生性瘢痕的潜在新型疗法,但需进一步临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Angiotensin II engagement of angiotensin II type 1 receptor (AT1R) is implicated in fibrogenesis, with AT1R blockers used clinically to attenuate cardiac and renal fibrosis. The authors tested the hypothesis that the AT1R blocker losartan could reduce postsurgical cutaneous scarring in rats. METHODS: Human dermal fibroblasts were treated with losartan and assessed for viability, contractile activity, migration, and profibrotic gene transcription by means of calcein, collagen gel, scratch, and quantitative reverse transcriptase polymerase chain reaction assays, respectively. Monocyte migration and adhesion to losartan-treated and control fibroblasts were examined. Losartan effects in vivo were assessed using a mechanical distraction hypertrophic scar model. Three days after incisions were made and closed on their backs, rats were assigned randomly to receive drinking water with or without losartan (1 mg/kg per day; n = 6 per group). Distraction devices were applied and activated up to day 14. On day 28, scars underwent cross-sectional area and elevation index analyses, and α-SMA (alpha-smooth muscle actin) and CD68 (monocyte/macrophage marker) immunostaining. RESULTS: Losartan-treated human dermal fibroblasts displayed decreased contractile activity, migration, and gene expression of transforming growth factor-β1, collagen I, and monocyte chemoattractant protein-1 relative to controls (p < 0.05). Monocyte migration and adhesion to losartan-treated fibroblasts were reduced (p < 0.01). Compared to controls, scars from losartan-treated rats demonstrated decreased cross-sectional area (19.4 ± 3.1 mm versus 45.0 ± 5.2 mm; p = 0.002), elevation index (1.5 ± 0.1 versus 2.6 ± 0.3; p = 0.003), and α-SMA and CD68 immunostaining (p < 0.001). CONCLUSIONS: Losartan decreases myofibroblast activity and reduces monocyte trafficking to cutaneous scar. These findings support losartan as a potential novel therapy for the prevention of hypertrophic scars.
引用
- Murphy A, LeVatte T, Boudreau C, et al. Angiotensin II Type I Receptor Blockade Is Associated with Decreased Cutaneous Scar Formation in a Rat Model. Plast Reconstr Surg. 2019. PMID: 31385893. doi:10.1097/PRS.0000000000006173
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。